Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

• Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
• Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
• Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
• Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
• Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
• Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
• Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
• Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction: ODAC — April 30, 2026 (00:00)
• Adjuvant CDK4/6 Inhibitors (13:03)
• Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
• Premenopausal Patients (30:52)
• Duration of Adjuvant Endocrine Treatment (38:44)
• Genomic Predictors of Chemotherapy Benefit (47:19)
• Neoadjuvant Treatment (55:13)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:

• Introduction (00:00)
• Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
• Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
• Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
• Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
• Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
• Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics:

• Introduction: Where We Are; Where We’re Heading (0:00)
• First-Line Treatment of BRCA Wild-Type Disease (9:14)
• First-Line Treatment of BRCA-Mutant Disease (38:48)
• Novel Approaches (47:49)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:

• Introduction (0:00)
• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)
• Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)

CME information and select publications

Featuring an interview with Prof Bernd Kasper, including the following topics:

• Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00)
• Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04)
• Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58)
• Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19)

CME information and select publications

Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics:

• Introduction (0:00)
• Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)
• Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)

CME information and select publications

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Virginia Kaklamani from the UT Health San Antonio MD Anderson Cancer Center in San Antonio, Texas, discuss patient cases and review relevant data on the management of ER-positive, HER2-negative metastatic breast cancer.

CME information and select publications